3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Advanced Solid Tumors
1
Interventions
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
pembrolizumab
4
Platinum
4
Cisplatin
4
Biopsy
4
1,2-diaminocyclohexaneplatinum II citrate
4
Radiotherapy, Intensity-Modulated
3
Cetuximab
3
(225)Ac-DOTA-c(RGDyK)
3
ipatasertib
2
cemiplimab
2
Radiotherapy
2
Radiation
2
Immunoglobulin G
2
Disulfides
2
Carboplatin
2
merphos
1
durvalumab
1
cabozantinib
1
atezolizumab
1
X-Rays
1
Transurethral Resection of Bladder
1
Taxes
1
Radiosurgery
1
Paclitaxel
1
Nivolumab
1
Methotrexate
1
Interviews as Topic
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.